M&A Deal Summary |
|
|---|---|
| Date | 2022-12-13 |
| Target | Nimbus Lakshmi |
| Sector | Life Science |
| Buyer(s) | Takeda |
| Sellers(s) | Nimbus Therapeutics |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1781 |
| Sector | Life Science |
| Employees | 47,455 |
| Revenue | 4.58T JPY (2025) |
Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was established in 1781 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 18 of 18 |
| Sector: Life Science M&A | 17 of 17 |
| Type: Divestiture M&A Deals | 3 of 3 |
| State: Massachusetts M&A | 4 of 4 |
| Country: United States M&A | 12 of 12 |
| Year: 2022 M&A | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-12-13 |
Nimbus Therapeutics - NDI-034858
Cambridge, Massachusetts, United States Nimbus Therapeutics's NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2009 |
| Sector | Life Science |
Nimbus Therapeutics is a biotechnology company pioneering the application of computational chemistry to design treatments for substantial and underserved human diseases. The company’s focus on metabolic diseases, cancer and immune-inflammatory disorders reflects the mechanistic relationship between these disorders, and Nimbus’ ability to rapidly tackle well validated targets as well as those that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry, resulting in medicines with high potency, selectivity and other desirable drug-like properties.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 3 of 3 |
| Type: Divestiture M&A Deals | 3 of 3 |
| State: Massachusetts M&A | 2 of 2 |
| Country: United States M&A | 3 of 3 |
| Year: 2022 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-12-13 |
Nimbus Therapeutics - NDI-034858
Cambridge, Massachusetts, United States Nimbus Therapeutics's NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. |
Sell | - |
